In 2017, Mould et al. developed a series of (4-cyanophenyl)glycine derivatives, through high-throughput screening and a fragment library search, that exhibited inhibitory effects against LSD1 and had the potential to treat acute myeloid leukemia (AML) [132]. Here, KDM1A is linked to acute myeloid leukemia.